Alpha Tau Medical Ltd. Receives Radioactive Material License for New Hampshire Facility

Alpha Tau Medical Ltd. announced the receipt of a radioactive material license from the State of New Hampshire Bureau of Public Health Protection for its new manufacturing facility in Hudson, New Hampshire. This license is a significant milestone for the company as it prepares for commercial operations of its Alpha DaRT® cancer therapy. The facility, which is being constructed in multiple phases, is expected to have a nameplate capacity of approximately 400,000 Alpha DaRT sources for local use. CEO Uzi Sofer highlighted the importance of this achievement and thanked the teams involved in the project. The company aims to begin producing Alpha DaRT treatments in 2026. Alpha DaRT is currently being evaluated in multiple clinical trials for the treatment of various cancers.